The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.

@article{Marchal2004TheRO,
  title={The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.},
  author={Laurent Grisoni Damien Marchal and G D'Haens and Gert Van Assche and S{\'e}verine Vermeire and M. Nasimul Noman and Marc Ferrante and Martin I. Hiele and Mirjam Bueno de Mesquita and Andr{\'e} D'Hoore and Freddy M. Penninckx and P. R. Rutgeerts},
  journal={Alimentary pharmacology & therapeutics},
  year={2004},
  volume={19 7},
  pages={749-54}
}
BACKGROUND By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications. AIM To test this hypothesis for intestinal resection in a cohort of 313 Crohn's disease patients treated with infliximab. Forty received one or more infusions prior to intestinal resection (31/40 within 12 weeks). METHODS The post-operative events of these patients were compared with those of a control group (infliximab naive… CONTINUE READING